| Affiliation: | (1) Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(2) Department of Medicine, Division of Clinical Nutrition, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(3) Department of Medicine, Division of Oncology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(4) Department of Ophthalmology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(5) Department of Neurology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(6) Department of Neurosurgery, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(7) Department of Pathology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA;(8) Department of Medicine, MetroWest Medical Center and Harvard Medical School, Framingham, MA 01702, USA |
| Abstract: | Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide. |
